BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 31694662)

  • 1. Apatinib potentiates irradiation effect via suppressing PI3K/AKT signaling pathway in hepatocellular carcinoma.
    Liao J; Jin H; Li S; Xu L; Peng Z; Wei G; Long J; Guo Y; Kuang M; Zhou Q; Peng S
    J Exp Clin Cancer Res; 2019 Nov; 38(1):454. PubMed ID: 31694662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PKI-587 enhances radiosensitization of hepatocellular carcinoma by inhibiting the PI3K/AKT/mTOR pathways and DNA damage repair.
    Xie Y; Liu C; Zhang Y; Li A; Sun C; Li R; Xing Y; Shi M; Wang Q
    PLoS One; 2021; 16(10):e0258817. PubMed ID: 34665844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway.
    Dai XF; Ding J; Zhang RG; Ren JH; Ma CM; Wu G
    Int J Radiat Biol; 2013 Sep; 89(9):724-31. PubMed ID: 23682582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autophagy inhibitor potentiates the antitumor efficacy of apatinib in uterine sarcoma by stimulating PI3K/Akt/mTOR pathway.
    Chen S; Yao L
    Cancer Chemother Pharmacol; 2021 Aug; 88(2):323-334. PubMed ID: 33978839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apatinib suppresses the migration, invasion and angiogenesis of hepatocellular carcinoma cells by blocking VEGF and PI3K/AKT signaling pathways.
    Song J; Guan Z; Song C; Li M; Gao Z; Zhao Y
    Mol Med Rep; 2021 Jun; 23(6):. PubMed ID: 33846786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sonic Hedgehog inhibition as a strategy to augment radiosensitivity of hepatocellular carcinoma.
    Tsai CL; Hsu FM; Tzen KY; Liu WL; Cheng AL; Cheng JC
    J Gastroenterol Hepatol; 2015 Aug; 30(8):1317-24. PubMed ID: 25682950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma.
    Yang C; Qin S
    Cancer Med; 2018 Sep; 7(9):4570-4583. PubMed ID: 30109780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secalonic Acid-F, a Novel Mycotoxin, Represses the Progression of Hepatocellular Carcinoma via MARCH1 Regulation of the PI3K/AKT/β-catenin Signaling Pathway.
    Xie L; Li M; Liu D; Wang X; Wang P; Dai H; Yang W; Liu W; Hu X; Zhao M
    Molecules; 2019 Jan; 24(3):. PubMed ID: 30678274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma.
    Bamodu OA; Chang HL; Ong JR; Lee WH; Yeh CT; Tsai JT
    Cells; 2020 Mar; 9(3):. PubMed ID: 32197467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Local anesthetic bupivacaine inhibits proliferation and metastasis of hepatocellular carcinoma cells via suppressing PI3K/Akt and MAPK signaling.
    Wang L; Guo W; Guan H; Yan N; Cai X; Zhu L
    J Biochem Mol Toxicol; 2021 Oct; 35(10):e22871. PubMed ID: 34338398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpinia oxyphylla oil induces apoptosis of hepatocellular carcinoma cells via PI3K/Akt pathway in vitro and in vivo.
    Hui F; Qin X; Zhang Q; Li R; Liu M; Ren T; Zhao M; Zhao Q
    Biomed Pharmacother; 2019 Jan; 109():2365-2374. PubMed ID: 30551496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
    Jung KH; Choi MJ; Hong S; Lee H; Hong SW; Zheng HM; Lee HS; Hong S; Hong SS
    Cancer Lett; 2012 Mar; 316(2):187-95. PubMed ID: 22182943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384.
    Leiker AJ; DeGraff W; Choudhuri R; Sowers AL; Thetford A; Cook JA; Van Waes C; Mitchell JB
    Clin Cancer Res; 2015 Jun; 21(12):2792-801. PubMed ID: 25724523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ERCC6L promotes the progression of hepatocellular carcinoma through activating PI3K/AKT and NF-κB signaling pathway.
    Chen H; Wang H; Yu X; Zhou S; Zhang Y; Wang Z; Huang S; Wang Z
    BMC Cancer; 2020 Sep; 20(1):853. PubMed ID: 32891122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upregulation of lncRNA FER1L4 suppresses the proliferation and migration of the hepatocellular carcinoma via regulating PI3K/AKT signal pathway.
    Wang X; Dong K; Jin Q; Ma Y; Yin S; Wang S
    J Cell Biochem; 2019 Apr; 120(4):6781-6788. PubMed ID: 30382631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Catalpol synergistically potentiates the anti-tumour effects of regorafenib against hepatocellular carcinoma via dual inhibition of PI3K/Akt/mTOR/NF-κB and VEGF/VEGFR2 signaling pathways.
    El-Hanboshy SM; Helmy MW; Abd-Alhaseeb MM
    Mol Biol Rep; 2021 Nov; 48(11):7233-7242. PubMed ID: 34596810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor is an effective radiosensitizer for colorectal cancer.
    Chen YH; Wei MF; Wang CW; Lee HW; Pan SL; Gao M; Kuo SH; Cheng AL; Teng CM
    Cancer Lett; 2015 Feb; 357(2):582-90. PubMed ID: 25497009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel role of apatinib as a multi-target RTK inhibitor in the direct suppression of hepatocellular carcinoma cells.
    Li X; Xu A; Li H; Zhang B; Cao B; Huang J
    Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1693-1701. PubMed ID: 29486282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Artemisia capillaris extract AC68 induces apoptosis of hepatocellular carcinoma by blocking the PI3K/AKT pathway.
    Yan H; Jung KH; Kim J; Rumman M; Oh MS; Hong SS
    Biomed Pharmacother; 2018 Feb; 98():134-141. PubMed ID: 29253760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Phosphatidylinositide3-Kinase/Akt pathway by BKM120 for radiosensitization in hepatocellular carcinoma.
    Liu WL; Gao M; Tzen KY; Tsai CL; Hsu FM; Cheng AL; Cheng JC
    Oncotarget; 2014 Jun; 5(11):3662-72. PubMed ID: 25004403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.